Remyelination strategies: New advancements toward a regenerative treatment in multiple sclerosis

Current Neurology and Neuroscience Reports

Volumn 6, Issue 3, 2006, Pages 229-235

  Stangel, Martin ^a   Trebst, Corinna ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR4; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR 2; HYALURONIC ACID; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INHIBITOR OF DIFFERENTIATION 2; INHIBITOR OF DIFFERENTIATION 4; INHIBITOR OF DIFFERENTIATION PROTEIN; LINGO 1 PROTEIN; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE; NERVE GROWTH FACTOR; NEU DIFFERENTIATION FACTOR; NOTCH1 RECEPTOR; OLIGODENDROCYTE TRANSCRIPTION FACTOR 1; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PLATELET DERIVED GROWTH FACTOR A; PROTEIN INHIBITOR; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX10; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CELL SURVIVAL; CELL TRANSFER; CLINICAL TRIAL; DISABILITY; GLIA CELL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MOLECULAR DYNAMICS; MULTIPLE SCLEROSIS; NERVE FIBER; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; REMYELINIZATION; SCHWANN CELL; STEM CELL TRANSPLANTATION;

ANIMALS; AXONS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA; REGENERATION;

EID: 33646771825     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-006-0010-2     Document Type: Article

References (67)

1. Lucchinetti C, Brück W, Parisi J, et al.: A quantitative analysis of oligodendrocytes in multiple sclerosis. A study of 113 cases. Brain 1999, 122:2279-2295.
2. Smith KJ, Blakemore WF, McDonald WI: The restoration of conduction by central remyelination. Brain 1981, 104:383-404.
3. Blakemore WF: Pattern of remyelination in the CNS. Nature 1974, 249:577-578.
4. Rodriguez M: A function of myelin is to protect axons from subsequent injury: implications for deficits in multiple sclerosis. Brain 2003, 126:751-752.
5. Stangel M, Hartung HP: Remyelinating strategies far the treatment of multiple sclerosis. Prog Neurobiol 2002, 68:361-376.
6. Zhao C, Fancy SP, Kotter MR, et al.: Mechanisms of CNS remyelination - the key to therapeutic advances. J Neurol Sci 2005, 233:87-91.
7. Baumann N, Pham-Dinh D: Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 2001, 81:871-927.
8. Stangel M: Remyelinating and neuroprotective treatments in multiple sclerosis. Expert Opin Invest Drugs 2004, 13:331-347.
9. Franklin RJ, Hinks GL: Understanding CNS remyelination: clues from developmental and regeneration biology. J Neurosci Res 1999, 58:207-213.
10. Lu QR, Sun T, Zhu Z, et al.: Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection. Cell 2002, 109:75-86.
11. Zhou Q, Anderson DJ: The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. Cell 2002, 109:61-73.
12. Marshall CA, Novitch BG, Goldman JE: Olig2 directs astrocyte and oligodendrocyte formation in postnatal subventricular zone cells. J Neurosci 2005, 25:7289-7298.
13. Arnett HA, Fancy SP, Alberta JA, et al.: bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 2004, 306:2111-2115.
14. Xin M, Yue T, Ma Z, et al.: Myelinogenesis and axonal recognition by oligodendrocytes in brain are uncoupled in Olig1-null mice. J Neurosci 2005, 25:1354-1365.
15. Gokhan S, Marin-Husstege M, Yung SY, et al.: Combinatorial profiles of oligodendrocyte-selective classes of transcriptional regulators differentially express myelin basic protein gene expression. J Neurosci 2005, 25:8311-8321.
16. Fancy SP, Zhao C, Franklin RJ: Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination. Mol Cell Neurosci 2004, 27:247-254.
17. Armstrong RC, Le TQ, Frost EE, et al.: Absence of fibroblast growth factor 2 promotes oligodendroglial repopulation of demyelinated white matter. J Neurosci 2002, 22:8574-8585.
18. Murtie JC, Zhou YX, Le TQ, Armstrong RC: In vivo analysis of oligodendrocyte lineage development in postnatal FGF2 null mice. Glia 2005, 49:542-554.
19. Butt AM, Dinsdale J: Fibroblast growth factor 2 induces loss of adult oligodendrocytes and myelin in vivo. Exp Neurol 2005, 192:125-133.
20. Fortin D, Rom E, Sun H, et al.: Distinct fibroblast growth factor (FGF)/ FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J Neurosci 2005, 25:7470-7479.
21. Mi S, Miller RH, Lee X, et al.: LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005, 8:745-751.
22. Back SA, Tuohy TM, Chen H, et al.: Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 2005, 11:966-972.
23. Nguyen D, Stangel M: Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. Dev Brain Res 2001, 128:77-81.
24. Tsai HH, Frost E, To V, et al.: The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 2002, 110:373-383.
25. Omari KM, John GR, Sealfon SC, Raine CS: CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis. Brain 2005, 128:1003-1025.
26. Dziembowska M, Tham TN, Lau P, et al.: A role for CXCR4 signaling in survival and migration of neural and oligodendrocyte precursors. Glia 2005, 50:258-269.
27. Johnson Z, Schwarz M, Power CA, et al.: Multi-faceted strategies to combat disease by interference with the chemokine system. Trends Immunol 2005, 26:268-274.
28. Bozzali M, Wrabetz L: Axonal signals and oligodendrocyte differentiation. Neurochem Res 2004, 29:979-988.
29. Chang A, Tourtellotte WW, Rudick R, Trapp BD: Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002, 346:165-173.
30. Michailov GV, Sereda MW, Brinkmann BG, et al.: Axonal neuregulin-1 regulates myelin sheath thickness. Science 2004, 304:700-703.
31. Sussman CR, Vartanian T, Miller RH: The ErbB4 neuregulin receptor mediates suppression of oligodendrocyte myelination. J Neurosci 2005, 25:5757-5762.
32. Taveggia C, Zanazzi G, Petrylak A, et al.: Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 2005, 47:681-694.
33. Chan JR, Watkins TA, Cosgaya JM, et al.: NGF controls axonal receptiveness to myelination by Schwann cells or oligodendrocytes. Neuron 2004, 43:183-191.
34. John GR, Shankar SL, Shafit-Zagardo B, et al.: Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat Med 2002, 8:1115-1121.
35. Jurynczyk M, Jurewicz A, Bielecki B, et al.: Inhibition of Notch signaling enhances tissue repair in an animal model of multiple sclerosis. J Neuroimmunol 2005, 170:3-10.
36. Minter LM, Turley DM, Das P, et al.: Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol 2005, 6:680-688.
37. Stidworthy MF, Genoud S, Li WW, et al.: Notch1 and Jagged1 are expressed after CNS demyelination, but are not a major rate-determining factor during remyelination. Brain 2004, 127:1928-1941.
38. Charles P, Hernandez MP, Stankoff B, et al.: Negative regulation of central nervous system myelination by polysialyated-neural cell adhesion molecule. Proc Natl Acad Sci 2000, 97:7585-7590.
39. Charles P, Reynolds R, Seilhean D, et al.: Re-expression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain 2002, 125:1972-1979.
40. Colognato H, Baron W, Avellana-Adalid V, et al.: CNS integrins switch growth factor signalling to promote target-dependent survival. Nat Cell Biol 2002, 4:833-841.
41. Decker L, French-Constant C: Lipid rafts and integrin activation regulate oligodendrocyte survival. J Neurosci 2004, 24:3816-3825.
42. Jaillard C, Harrison S, Stankoff B, et al.: Edg8/S1P5: An oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 2005, 25:1459-1469.
43. Lucchinetti C, Brück W, Parisi J, et al.: Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
44. Arnett HA, Wang Y, Matsushima GK, et al.: Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci 2003, 23:9824-9832.
45. Arnett HA, Mason J, Marino M, et al.: TNFa promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001, 4:1116-1122.
46. Bieber AJ, Kerr S, Rodriguez M: Efficient central nervous system remyelination requires T cells. Ann Neurol 2003, 53:680-684.
47. Mason JL, Suzuki K, Chaplin DD, Matsushima GK: Interleukin-1b promotes repair of the CNS. J Neurosci 2001, 21:7046-7052.
48. Foote AK, Blakemore WF: Inflammation stimulates remyelination in areas of chronic demyelination. Brain 2005, 128:528-539.
49. Kotter MR, Setzu A, Sim FJ, et al.: Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Glia 2001, 35:204-212.
50. Kotter MR, Zhao C, van Rooijen N, Franklin RJ: Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005, 18:166-175.
51. Li WW, Setzu A, Zhao C, Franklin RJ: Minocycline-mediated inhibition of microglia activation impairs oligodendrocyte progenitor cell responses and remyelination in a non-immune model of demyelination. J Neuroimmunol 2005, 158:58-66.
52. Schwartz M, Kipnis J: Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci 2005, 233:163-166.
53. Frank JA, Richert N, Lewis B, et al.: A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients. Mult Scler 2002, 8:24-29.
54. Leist M, Ghezzi P, Grasso G, et al.: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242.
55. Savino C, Pedotti R, Baggi F, et al.: Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 2005, In press.
56. Ehrenreich H, Aust C, Krampe H, et al.: Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 2004, 19:195-206.
57. Rodriguez M, Lennon VA: Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 1990, 27:12-17.
58. Trebst C, Stangel M: Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis. Curr Pharm Design 2006, 12:241-249.
59. Bieber AJ, Warrington A, Asakura K, et al.: Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Glia 2002, 37:241-249.
60. Ciric B, Howe CL, Paz Soldan M, et al.: Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol 2003, 13:608-616.
61. Stangel M, Hartung HP: Despair of repair. Immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002, 72:1-4.
62. Duncan ID, Grever WE, Zhang SC: Repair of myelin disease: strategies and progress in animal models. Mol Med Today 1997, 3:554-561.
63. Joannides A, Gaughwin P, Schwiening C, et al.: Efficient generation of neural precursors from adult human skin: astrocytes promote neurogenesis from skin-deived stem cells. Lancet 2004, 364:172-178.
64. Mezey É, Key S, Vogelsang G, et al.: Transplanted bone marrow generates new neurons in human brains. Proc Natl Acad Sci 2003, 100:1364-1369.
65. Pluchino S, Quattrini A, Brambilla E, et al.: Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 2003, 422:688-694.
66. Pluchino S, Zanotti L, Rossi B, et al.: Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005, 436:266-271.
67. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al.: Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.